ASND

Ascendis Pharma

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/07/26

Business Summary

AdaptHealth provides home medical equipment and related healthcare services, generating revenue through equipment rentals, sales, and recurring patient service contracts reimbursed by insurers and government programs. Cash flow is driven by scale in distribution, payer relationships, and operational logistics rather than proprietary technology. The moat, such as it is, comes from entrenched referral networks, reimbursement know-how, and the complexity of coordinating equipment delivery and compliance across a fragmented patient base. However, with a 0.40% ROIC and -4.70% Operating Margin, the durability of that moat depends heavily on execution efficiency and balance sheet discipline rather than structural pricing power.

VALUATION

P/E

-

Market Cap ($M USD)

$14,690

Forward P/E

23.6

PEG

0.5

PRICE TO SALES

17.3

PRICE TO BOOK

-

EV / EBITDA

-113.6

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$4.34

Next Year EPS Growth Estimate

$10.15

Next Year Revenue Growth Estimate

41.70%

Return on Equity (ROE)

140.10%

Operating Margin

-18.90%

Debt-to-Equity

-

Piotroski F-Score

6

Altman Z-Score

5.5

Return on Invested Capital (ROIC)

-20.80%%

Current Ratio

1

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At 0.5x Price/Sales and 1.1x Price/Book, the market is clearly pricing AdaptHealth as a distressed asset, not a stable operator. A 9.8 Forward P/E and 0.8 PEG Forward signal that, on paper, growth is available at a discount, but the 1.1 Altman Z-Score places the company firmly in financial distress territory, meaning solvency risk is non-trivial. Operating Margin of -4.70% and ROIC of 0.40% confirm that capital is not being deployed efficiently, despite a 7.20% Return on Equity. This is a classic deep value setup where the valuation looks optically cheap, but the balance sheet and profitability profile justify a severe discount. The market is not mispricing safety — it is demanding compensation for real financial fragility.

AI Exposure / Tech Reliance

As a Medical Devices company within Healthcare, AdaptHealth operates in a segment that can benefit from data integration, remote monitoring, and AI-assisted patient management. The ability to optimize equipment utilization, logistics, and reimbursement workflows through technology could structurally improve margins over time. However, with current Operating Margin at -4.70%, execution — not innovation — is the immediate hurdle.

The Bull Case

A value or GARP investor could justify a position based on pure multiple compression and recovery math. A 9.8 Forward P/E combined with a 0.8 PEG Forward implies growth is priced below its expected trajectory, while a 0.5 Price/Sales ratio suggests the market assigns minimal value to each dollar of revenue. The Piotroski F-Score of 5 indicates financials that are mediocre but not collapsing, and a Current Ratio of 1 shows short-term obligations are covered, albeit tightly. Return on Equity at 7.20% demonstrates that equity capital is still generating positive returns, and with Market Cap at $1,654M, even modest margin normalization could create significant equity re-rating. For a deep value fund, this is a balance sheet repair and margin recovery thesis trading at depressed sales and book multiples.

The Bear Case

The red flags are loud. Debt/Equity at 5.70% signals meaningful leverage, and when paired with a 1.1 Altman Z-Score, the capital structure risk becomes the dominant narrative. Operating Margin of -4.70% and ROIC of 0.40% indicate a business that is barely generating economic value, while EPS Next Year (Est.) at -$0.52 suggests earnings volatility or potential deterioration ahead despite a current EPS of 7.3. Sales Growth Next Year listed at $1.24 lacks evidence of scalable profitability, and Institutional Ownership at 12.88% reflects limited strong-handed sponsorship. This is not a clean turnaround — it is a leveraged operator trying to stabilize profitability under tight liquidity conditions.

Market Sentiment & Smart Money

Short Interest %

7.50%

Analyst Consensus

1.17

Average Analyst Price Target

$290.12

Institutional Ownership %

107.40%

1-Year Beta

0.31

Insider Buying % (6 Mo)

0.80%%

Distance to 52-Week High

96.30%%

Distance to 52-Week Low

168.30%%